



The University of  
**Nottingham**

UNITED KINGDOM · CHINA · MALAYSIA

Poston, Lucilla and Igosheva, Natalia and Mistry, Hiten D. and Seed, Paul T. and Shennan, Andrew H. and Rana, Sarosh and Karumanchi, S. Ananth and Chappell, Lucy C. (2011) The role of oxidative stress and antioxidant supplementation in pregnancy disorders. *American Journal of Clinical Nutrition*, 94 (6Suppl). 1980S-1985S. ISSN 1938-3207

**Access from the University of Nottingham repository:**

<http://eprints.nottingham.ac.uk/44262/8/Poston%20AJCN%20review%20-%2044262.pdf>

**Copyright and reuse:**

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the University of Nottingham End User licence and may be reused according to the conditions of the licence. For more details see:  
[http://eprints.nottingham.ac.uk/end\\_user\\_agreement.pdf](http://eprints.nottingham.ac.uk/end_user_agreement.pdf)

**A note on versions:**

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact [eprints@nottingham.ac.uk](mailto:eprints@nottingham.ac.uk)

# **The Role of Oxidative Stress and Antioxidant Supplementation in Pregnancy Disorders**

Lucilla Poston<sup>1</sup>, Natalia Igosheva<sup>1</sup>, Hiten D. Mistry<sup>1</sup>, Andrew H. Shennan<sup>1</sup>, S Ananth Karumanchi<sup>2</sup>, Lucy C. Chappell<sup>1</sup>.

<sup>1</sup>Division of Reproduction and Endocrinology, King's College London, Kings Health Partners Women' Health Clinical Academic Grouping

<sup>2</sup>Hughes Medical Institute, Center for Vascular Biology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass; Division of Epidemiology, Statistics

## **Address for correspondence**

Professor Lucilla Poston, Maternal and Fetal Research Unit

10<sup>th</sup> floor North Wing, St.Thomas' Hospital, London SE1 7EH

Email [lucilla.poston@kcl.ac.uk](mailto:lucilla.poston@kcl.ac.uk)

Tel (44) 207 188 3639

Fax (44) 207 620 1227

Sources of Support; Tommy' the Baby Charity, The Wellcome Trust

Running Head: Oxidative Stress and Pregnancy Disorders

Abstract 250 words max

1 Oxidative stress is widely implicated in reproductive performance including infertility,  
2 miscarriage, diabetes-related congenital malformations and pre-eclampsia. Maternal  
3 obesity is a strong risk factor for pre-eclampsia, and recently, in an animal model of  
4 maternal obesity we have reported evidence of oxidative stress in the oocytes of  
5 obese animals prior to pregnancy as well as in early stage embryos. This adds to the  
6 growing evidence for a greater focus on the pre-conceptual period in prevention of  
7 pregnancy disorders including those related to oxidative stress. Our research has  
8 also focussed on the role of free radicals and antioxidant capacity in pre-eclampsia.  
9 Assessment by measurement of markers of lipid peroxidation or of antioxidant  
10 capacity has provided unequivocal evidence for oxidative stress in this disorder.  
11 Partial failure of the process of placentation has been implicated, with recent  
12 evidence proposing that ischaemia reperfusion in the placenta may contribute to  
13 oxidative stress in trophoblast. Endoplasmic reticulum stress in the placenta may  
14 also play a role. We and others have performed randomised controlled trials to  
15 determine whether early supplementation with vitamins C and E in women at risk of  
16 pre-eclampsia may be beneficial but these studies have shown no evidence for  
17 prevention of pre-eclampsia. Whether this represents an inappropriate antioxidant  
18 strategy or whether supplementation has been too late in gestation to be beneficial is  
19 not known. Other potential approaches to prevention of pre-eclampsia through  
20 amelioration of oxidative stress include provision of supplements in the pre-  
21 conceptual period, selenium supplements, anti-peroxynitrite strategies and statins.

22

23 Oxidative stress, defined as an imbalance between pro-oxidants and antioxidant  
24 capacity, has been implicated in sub-optimal reproductive performance from the  
25 earliest stages of development through to labour and delivery. Reactive oxygen  
26 species (ROS) are substances with one or more unpaired electrons; because of this  
27 ROS are highly reactive, interacting with lipids, proteins or DNA leading to oxidation  
28 and cellular malfunction which may initiate pathological processes. The most  
29 commonly produced of the ROS in mammals is superoxide. Depletion of antioxidant  
30 capacity, whether through low abundance of non-enzymatic (e.g. vitamins C, E,  
31 glutathione) or enzymatic (e.g. superoxide dismutase, glutathione peroxidases,  
32 catalase) antioxidants renders the cell vulnerable to oxidative attack, even under  
33 physiological situations where redox status is maintained through careful balance of  
34 a low level of synthesis of reactive oxygen species and the pathways of cellular  
35 defence (Raijmakers MTM et al, Current Pharm Design 2004; Forman HJ et al  
36 Biochemistry 2010).

37

### 38 **Oxidative Stress and Fertility.**

39 Gametes are vulnerable to oxidative attack (Ruder EH et al, Human Reproduction  
40 Update 2009; Aitkin RJ and Lullis Mol Human Reproduction 2010). Reduced fertility  
41 in men has been associated with oxidative damage to sperm. Human sperm is  
42 vulnerable to oxidant attack as it contains a very high content of polyunsaturated  
43 fatty acids, which are necessary to facilitate fusion with the oocyte, but are rich in  
44 double bonds which are prone to oxidation. The spermatozoa of subfertile patients  
45 contain high levels of 8-hydroxy-20-deoxyguanosine (8OHdG), the oxidation product  
46 formed when DNA is subjected to attack by ROS (Kodama H et al., Fertil and

47 Sterility 1997). De Iuliis and colleagues have recently reported the presence of  
48 8OHdG adducts in human spermatozoa to be highly correlated with DNA strand  
49 breaks, determined using the TUNEL assay (De Iuliis et al., 2009). In a recent review  
50 Aitken and De Iuliis list the possible mechanisms which may result in DNA strand  
51 breaks in human sperm (Aitken and De Iuliis 2010). These include reduced  
52 antioxidant capacity in epididymal plasma or seminal fluid (as may occur in  
53 smokers), infection and iatrogenic ROS synthesis. These authors propose that the  
54 latter is predominantly derived from mitochondria and may be exacerbated in  
55 damaged sperm. It is suggested that damaged sperm, characterised by retention of  
56 residual cytoplasm, abnormal chromatin remodelling or abnormally high content of  
57 polyunsaturated fatty acids, will default to preferential activation of pathways of  
58 apoptosis. This in turn will lead to excess mitochondrial ROS synthesis.  
59 Mitochondrial oxidative phosphorylation necessarily leads to synthesis of free  
60 radicals through electron 'leakage' from the electron transfer pathway leading to  
61 generation of superoxide ( $O_2^{\bullet}$ ) and hydroxyl radicals ( $OH^{\bullet}$ ) and mitochondrial  
62 activation in association with apoptosis can lead to excessive ROS synthesis and  
63 'auto' attack of the already vulnerable sperm, DNA oxidation and subsequent  
64 malfunction. Improved sperm function *in vitro* by addition of antioxidants has been  
65 repeatedly shown (Baker HW et al Fertility and Sterility 1996; Donnelly ET et al,  
66 Mutagenesis 2000) and it might be anticipated that antioxidant supplements would  
67 improve fertility in sub-fertile men. Several studies suggest that antioxidant  
68 supplementation may be of benefit in those subfertile men with proven oxidative  
69 damage in the sperm but there is no consensus of opinion in regard to the  
70 appropriate supplement or dose, and infertile men are not routinely tested for DNA  
71 fragmentation (Deepinder F et al, Endocr Pract 2008). One study has reported the

72 potential benefit of antioxidant supplementation (1 g vitamin C and 1 g vitamin E  
73 daily for 2 months) in men with already proven high levels of DNA oxidative damage  
74 and one failed ICSI attempt. The majority of the men demonstrated a reduction in  
75 DNA fragmented spermatozoa and improved ICSI success (Greco E, Human  
76 Reproduction 2005). An improvement in fertility was also found in men with a high  
77 DNA fragmentation index instructed to consume a diet rich in antioxidants or  
78 commercial multivitamins containing beta-carotene, vitamin C, vitamin E, and zinc for  
79 at least 3 months (Gill Villa AM Fertility and Sterility 2009). Our group have recently  
80 systematically reviewed the effect of oral antioxidants on male subfertility and  
81 concluded that supplementation could improve sperm quality and/or pregnancy  
82 rates; however large adequately powered trials using individual antioxidants are  
83 required (Ross et al., 2010).

84

85 Oxidative stress also influences fertility in species other than man. An interesting  
86 corollary from the animal kingdom, recently published, is the recognition that  
87 amongst males of several avian species, those which are more brightly coloured are  
88 the more fertile. In the Great Tit (*Parus major*), the intensity of the yellow colour of  
89 the male breast has been related to the degree of carotenoid sufficiency, which in  
90 turn has been found to protect the sperm from lipid peroxidation, and thereby  
91 improve chances of reproductive success (Helfenstein F et al Eco Letters 2010).

92

93 Oocyte quality is also affected by oxidative stress, and lower fertility rates in cigarette  
94 smokers, or in association with high levels of alcohol consumption, have been have  
95 been linked to increased ROS synthesis (Paszkowski T et al, Clin Chim Acta 236;  
96 1995; Jensen TK et al, BMJ 1998;317; Eggert J et al, Fertil Steril 2004; 81; Ruder

97 EH et al 2008). As in many cellular processes, a low level of ROS synthesis fulfils an  
98 important role in cell signal transduction pathways, and in the oocyte, is a  
99 prerequisite for the first meiotic phase (MI) and also a requirement for  
100 folliculogenesis. However excessive ROS synthesis will impair oocyte maturation  
101 (MII) and inadequate intracellular antioxidant capacity, particularly low  
102 concentrations of reduced glutathione (GSH), can limit successful ovulation and  
103 fertilisation (Ruder et al, 2008). Whilst there is good evidence that dietary antioxidant  
104 supplements can modulate fertility in rodents, there is as yet very limited evidence to  
105 suggest that periconceptual antioxidant supplementation should be recommended  
106 to improve fertility in women (Ruder et al, 2008; Cetin I et al, Human Reprod Update  
107 16; 2010).

108

109 *In vitro* fertilization is also affected by excessive ROS in the embryo culture media,  
110 and the routine practice of incubation in a low oxygen tension prevents embryo  
111 arrest and enhances the chance of successful fertilization. (Ruder et al;, 2008)

112

113 Obese women have a high rate of infertility, and assisted conception is often  
114 associated with a low success of oocyte fertilization, or of failure of embryo  
115 development (Pandey S and Battacharya S; Womens Health 2010). Several  
116 biomarkers of oxidative stress are increased in the blood of obese non-pregnant and  
117 pregnant individuals (Iyer A et al Nature Rev Endocrinol 2010; Jarvie E et al, Clin  
118 Science 2010). In a recent study we addressed the hypothesis that oxidative stress  
119 may be a contributory factor to reduced fertility in obese pregnancies (Igosheva N et  
120 al, PlosOne 2010). We explored the hypothesis that increased substrate availability

121 for mitochondrial respiration may lead to oxidative stress in the oocyte and  
122 developing embryo. It is proposed that a high plane of nutrition may lead to  
123 excessive enrichment of the reproductive milieu (Robker RL et al, J Clin Endocrinol  
124 Metab 2009) and high rates of metabolism may compromise oocyte and embryo  
125 development, potentially through excessive mitochondrial ROS synthesis. We  
126 determined whether obesity in the mouse is associated with increased mitochondrial  
127 activity in oocytes and early stage embryos. C67BL/6J mice were fed a highly  
128 palatable diet or normal laboratory chow. After six weeks of the diet, females were  
129 induced to superovulate by hCG and oocytes were collected by puncture of pre-  
130 ovulatory follicles. Zygotes and blastocysts were collected after successful mating  
131 with lean males after 24 and 84hr post hCG. Mitochondrial membrane potential, an  
132 indirect measure of mitochondrial activity, was determined with a mitochondrial  
133 specific membrane fluoroprobe (TMRM). Hyperpolarization of the membrane was  
134 observed in oocytes and zygotes retrieved from the obese females when compared  
135 to those from the lean animals. Redox status was assessed by measurement of the  
136 oxidative status of the pyridine nucleotide (NAD(P)H) and the flavine nucleotide  
137 FAD<sup>++</sup>, by measurement of autofluorescence. Both showed evidence of increased  
138 oxidation in oocytes and zygotes from the obese females. Direct measurement of  
139 free radical generation in *in vitro* 'real time' using the fluorescent dye dihydroethidium  
140 (HEt) also showed clearly that obesity was associated with increased ROS  
141 synthesis. Measurement of reduced glutathione using the fluorescent dye  
142 monochlorobimane (MCB) provided evidence of reduced cellular antioxidant  
143 capacity. ROS can also affect mitochondrial abundance and copy number and we  
144 found in the oocytes that mitochondrial DNA copy number was increased together  
145 with expression of nuclear genes encoding mitochondrial DNA transcription factors



146 (mtTFAM and NRF1). The ability of zygotes to develop to the blastocyst stage was  
147 also reduced in the obese mice. To our knowledge this is the only study to have  
148 directly addressed redox status in oocytes and early embryos in obese animals and  
149 supports the hypothesis that oxidative stress may play a role in suboptimal fertility in  
150 obesity.

151 Using the same model of murine obesity our laboratory also reported previously that  
152 the offspring later become hypertensive, demonstrate glucose intolerance and are  
153 fatter than controls (Samuelsson et al, Hypertension 2008). We also reported that  
154 the adult (3 month old) male offspring of the obese dams display a decrease in the  
155 mitochondrial electron transport chain as shown by reduced mitochondrial-linked  
156 complex II-III (Shelley, McConnett et al, Am J Physiol 2009). Thus abnormal  
157 mitochondrial function is an accompaniment of obesity from the earliest stages of  
158 life. Whether this played a role in development of the phenotype described in the  
159 adult offspring of the obese dams, or whether it was a consequence remains to be  
160 determined but there is growing evidence that that the mitochondrion, which itself is  
161 particularly susceptible to DNA damage and has a modest capacity for repair, may  
162 be involved in the epigenetic processes associated with the developmental of  
163 adulthood disorders arising from nutritional imbalance *in utero* and in early post natal  
164 life (Simmons RA Rev End Met Dis 2007). **Figure?**

165

### 166 **Oxidative Stress and Early Pregnancy Loss.**

167 Oxidative stress has also been implicated in early miscarriage. Jauniaux and Burton  
168 have suggested that miscarriage may arise from premature oxygenation of the early  
169 embryonic environment. Using an O<sub>2</sub> probe in women prior to first trimester

170 termination they showed a steep rise in placental pO<sub>2</sub> between 8 and 12 weeks of  
171 gestation, coincident with the establishment of maternal perfusion. Oxygenation was  
172 accompanied by upregulation of a battery of antioxidant defences including  
173 increased expression of catalase, glutathione peroxidase and Cu/Zn and Mn  
174 superoxide dismutase (Jauniaux E et al, Am J Pathol 2000). The same group  
175 showed an increase in markers of oxidative stress in placental tissue from early  
176 pregnancy losses compared with controls and suggested that increased ROS  
177 generation may arise from a consequence of the premature establishment of  
178 maternal placental perfusion (Burton G, Jauniaux E, J Soc Gynecol Invest 2004).  
179 Whilst it might be anticipated that antioxidant supplements may provide some  
180 protection against miscarriage, metanalysis of all relevant studies suggests no  
181 substantive evidence for antioxidant supplements providing any benefit (Rumbold A,  
182 Middleton, Crowther, Cochrane Review 2005).

183

#### 184 **Oxidative Stress and Pre-eclampsia.**

185 Pre-eclampsia, which affects approximately 2-7% of all pregnancies, is a syndrome  
186 associated with multi-organ dysfunction, characterised by new onset hypertension  
187 (blood pressure  $\geq 140/90$  mmHg) and proteinuria ( $\geq 300$  mg/L) after 20 weeks'  
188 gestation (Brown et al., 2001). Other complications including stroke, convulsions,  
189 pulmonary edema, liver failure and thrombus formation make this a potentially life  
190 threatening condition for the mother and child (Villar J, Say L, Gulmezoglu AM et al.  
191 Eclampsia and pre-eclampsia: a worldwide health problem for 2000 years. In  
192 Critchley H, MacLean A, Poston L, Walker J '*Pre-eclampsia*'. London (UK) RCOG  
193 Press 2003; 189-207). Infant mortality and morbidity may also be may compromised

194 by placental insufficiency leading to poor fetal growth. The precise mechanisms that  
195 lead to pre-eclampsia, which often occurs without warning and may follow a  
196 precipitous course are not known, but failure of the normal processes of  
197 placentation, followed by inadequate placental perfusion would seem to be a  
198 necessary prelude to the cascade of molecular events which culminate in the  
199 maternal syndrome (Redman CWG and Sargent IL, Placental Stress and Pre-  
200 eclampsia, Placenta 2009). This is characterised by a marked exaggeration of the  
201 normal, mild inflammatory response which occurs in the pregnant woman, and is  
202 accompanied by vascular endothelial cell and platelet activation, and impairment of  
203 vascular endothelial dilator function (Redman CW, [Sargent IL](#). Preeclampsia and the  
204 systemic inflammatory response. [Semin Nephrol](#). 2004 Nov;24(6):565-70).

205

206 The normal process of placentation involves remodelling of the maternal spiral  
207 arteries, the small resistance arteries of the uterine circulation responsible for blood  
208 supply to the placental intervillous space. The normally thick muscular wall of the  
209 spiral artery is rendered flaccid and non-contractile as the cytotrophoblast (placental  
210 epithelial cells) invade the decidua and myometrium of the uterine wall (Pijnenborg et  
211 al., 1980; Jauniaux et al., 2006). In pre-eclampsia this process is often incomplete  
212 and some vessels retain the smooth muscle layer ([Whitley GS](#), Cartwright JE.  
213 Cellular and Molecular Regulation of Spiral Artery Remodelling: Lessons From the  
214 Cardiovascular Field. [Placenta](#). 2010 Mar 30; doi:10.1016/j.placenta.2010.03.002 ).  
215 This in turn leads to reduced placental perfusion. The resultant hypoxia, together  
216 with intermittent reperfusion, is hypothesised to provoke ROS synthesis in the  
217 placenta (Burton, Hwang, Cindrova Davies, Placenta 2009; 23; S43). Numerous

218 studies describe elevation of markers of oxidative stress in placental tissue from  
219 women with pre-eclampsia (Raijmakers, 2004 Current Pharmaceutical Desgin;  
220 Burton, Hwang etc 2009). Periods of ischaemia followed by reperfusion are  
221 associated with conversion of xanthine dehydrogenase to xanthine oxidase which is  
222 a potent source of superoxide ( $O_2^\bullet$ ) and xanthine oxidase activity is increased in the  
223 placentae of affected women (Many A, Hubel CA, Fisher SJ, Roberts JM, Zhou Y.  
224 Invasive cytotrophoblasts manifest evidence of oxidative stress in preeclampsia. Am  
225 J Pathol. 2000 Jan;156(1):321-31). Recently, Burton *et al* have shown that hypoxia  
226 in placental tissue leads to endoplasmic reticulum (ER) stress, and activation of the  
227 unfolded protein response (UPR) (Burton GJ, H-W Yung Placenta 2009; 23; S43).  
228 ER stress leads to accumulation of misfolded proteins, which is the trigger for the  
229 unfolded protein response (UPR) that aims to restore ER homeostatic balance.  
230 Failure of this mechanism, which attempts to reconfigure the folding of proteins can  
231 lead to activation of apoptotic pathways and protein synthesis inhibition, which have  
232 been implicated by Burton and colleagues in the pathway to fetal growth restriction.  
233 Moreover ER stress is coupled to ROS synthesis, and ROS synthesis will increase  
234 with the degree of maternal spiral artery malfunction (Burton GJ, H-W Yung Placenta  
235 2009; 23; S43). Together ER stress and ROS synthesis are proposed to activate a  
236 cascade of pathways leading to cytokine release, prostaglandin synthesis, increased  
237 expression of anti-angiogenic factors (e.g. soluble Flt-1) and activation of apoptotic  
238 pathways. Other suggested contributors to ROS production include an activating  
239 autoantibody to the angiotensin 2 (ATII) receptor which is proposed to lead to ROS  
240 synthesis through activation of NADPH oxidase, a key cellular source of superoxide  
241 (Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y. Angiotensin  
242 receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with

243 disease severity. Hypertension. 2010 Feb;55(2):386-93). As summarised in figure 1,  
244 it is hypothesised that these disturbances of placental function may be causative of  
245 the maternal syndrome.

246

## 247 **Antioxidant Supplementation in Pre-eclampsia**

248 The recognition of oxidative stress in the placenta, and also in the maternal  
249 circulation, prompted us to evaluate the potential benefit of prophylactic antioxidant  
250 supplementation in women with known risk of pre-eclampsia. At first we evaluated  
251 the effect of vitamin E and C supplements in women with known risk factors for pre-  
252 eclampsia (abnormal uterine artery Doppler waveform or previous pre-eclampsia)  
253 (Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt BJ, Parmar K, Bewley SJ,  
254 Shennan AH, Steer PJ, Poston L. Effect of antioxidants on the occurrence of pre-  
255 eclampsia in women at increased risk: a randomised trial. Lancet. 1999 Sep  
256 4;354(9181):810-6). The study was designed to test the hypothesis that antioxidants  
257 would lead to reduction of biomarkers of maternal endothelial dysfunction, the ratio  
258 of Plasminogen Activator Inhibitor (PAI)-1: PAI-2 (PAI-1:PAI-2) being chosen as the  
259 primary outcome. In this small randomised controlled trial of 283 women, we showed  
260 that supplementation with 1gm vitamin C and 400IU of vitamin E daily from around  
261 16 weeks' of gestation until delivery was associated with significant reduction in the  
262 PAI-1:PAI-2 ratio. We also reported a reduction in the plasma concentration of 8-epi  
263 prostaglandin F<sub>2α</sub>, a marker of lipid peroxidation, in association with elevation of the  
264 plasma vitamin C and E concentrations (Chappell LC, Seed PT, Kelly FJ, Briley A,  
265 Hunt BJ, Charnock-Jones DS, Mallet A, Poston L. Vitamin C and E supplementation  
266 in women at risk of preeclampsia is associated with changes in indices of oxidative

267 stress and placental function. *Am J Obstet Gynecol.* 2002 Sep;187(3):777-84).

268 Although not powered for pregnancy outcome the number of women who developed

269 pre-eclampsia was lower in the antioxidant group compared with those women

270 taking the placebo preparation. Encouraged by the evidence that antioxidants could

271 improve oxidative stress and by the suggestion of reduced occurrence of the

272 disease, we performed a randomised controlled trial in 2404 women, adequately

273 powered to detect a difference in the incidence of pre-eclampsia, the primary

274 outcome (Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH; Vitamins in Pre-

275 eclampsia (VIP) Trial Consortium. Vitamin C and vitamin E in pregnant women at

276 risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. *Lancet.* 2006

277 Apr 8;367(9517):1145-54). Although treatment compliance was good and despite

278 evidence for improved antioxidant capacity in the blood, there was no difference in

279 the number of women who developed pre-eclampsia between intervention (15%)

280 and placebo (16%) arms. There was also a small but statistically significant increase

281 in the incidence of low birthweight in the intervention arm (Risk Ratio 1.15 (1.02 to

282 1.30). Three other large randomised controlled trials including one undertaken by the

283 WHO in developing countries have also shown a lack of effect, conclusively proving

284 that this antioxidant regime does not prevent pre-eclampsia either in high risk (Villar

285 J, Purwar M, Merialdi M, Zavaleta N, Thi Nhu Ngoc N, Anthony J, De Greeff A,

286 Poston L, Shennan A; WHO Vitamin C and Vitamin E trial group. *World Health*

287 *Organisation multicentre randomised trial of supplementation with vitamins C and E*

288 *among pregnant women at high risk for pre-eclampsia in populations of low*

289 *nutritional status from developing countries. BJOG.* 2009 May;116(6):780-8) or lower

290 risk (Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS; ACTS

291 Study Group. *Vitamins C and E and the risks of preeclampsia and perinatal*

292 complications. N Engl J Med. 2006 Apr 27;354(17):1796-806; Roberts JM, Myatt L,  
293 Spong CY, Thom EA, Hauth JC, Leveno KJ, Pearson GD, Wapner RJ, Varner MW,  
294 Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Samuels P,  
295 Sciscione A, Harper M, Smith WJ, Saade G, Sorokin Y, Anderson GB; Eunice  
296 Kennedy Shriver National Institute of Child Health and Human Development  
297 Maternal-Fetal Medicine Units Network. Vitamins C and E to prevent complications  
298 of pregnancy-associated hypertension. N Engl J Med. 2010 Apr 8;362(14):1282-91)  
299 women. Two of these have also shown an increase in the incidence of gestational  
300 hypertension in the intervention arm (Poston; Roberts), although the observation of  
301 low birthweight found in our RCT has not been replicated in the subsequent trials.

302

### 303 **Why do antioxidants Vitamin C and E not prevent Pre-eclampsia?**

304 Despite overwhelming evidence for oxidative stress in pre-eclampsia, a regime of a  
305 vitamin C and E supplementation does not prevent pre-eclampsia. Amongst the  
306 several potential explanations, the first must be that oxidative stress, whilst  
307 undoubtedly present, plays no causative role in the aetiology of the disorder. This  
308 counters all the observational studies and extensive *in vitro* analyses detailing the  
309 responsible signalling pathways potentially involved. Until evidence to the contrary is  
310 presented, this explanation cannot be discounted. The second is that this antioxidant  
311 regime is inappropriate. Longitudinal blood sampling was performed in a sub-group  
312 of participants in the second trial of vitamins C and E from our group;  
313 supplementation leads to a significant fall in the plasma concentrations of  $\gamma$ -  
314 tocopherol (Figure 2). The vitamin E preparation was given as natural source RRR  $\alpha$   
315 tocopherol, the stereoisomer that is preferentially absorbed in humans. The fall in  $\gamma$ -

316 tocopherol might be anticipated since dietary  $\alpha$  and  $\gamma$  tocopherol compete in the liver  
317 for the tocopherol transfer protein (TTP) which facilitates uptake into the circulation  
318 (Hosomi A, Arita M, Sato Y, Kiyose C, Ueda T, Igarashi O, Arai H, Inoue K. Affinity  
319 for alpha-tocopherol transfer protein as a determinant of the biological activities of  
320 vitamin E analogs. FEBS Lett. 1997 Jun 2;409(1):105-8). However  $\gamma$ -tocopherol has  
321 biological activity, including anti-inflammatory properties; lowering of the blood  
322 concentration may impair the capacity to combat the inflammatory response of pre-  
323 eclampsia (Devaraj S, Jialal I. Failure of vitamin E in clinical trials: is gamma-  
324 tocopherol the answer? Nutr Rev. 2005 Aug;63(8):290-3; Reiter E, Jiang Q, Christen  
325 S. Anti-inflammatory properties of alpha- and gamma-tocopherol. Mol Aspects Med.  
326 2007 Oct-Dec;28(5-6):668-91). It was of interest that antioxidant supplementation  
327 also led to a significant fall in the plasma concentration of sflt-1, the anti-angiogenic  
328 soluble receptor for VEGF-1 which has been strongly implicated in development of  
329 pre-eclampsia, and a rise in placenta growth factor (PIGF) (Figure 3), but had no  
330 effect on endoglin. Studies *in vitro* have also shown that vitamins C and E prevent  
331 elevation of sFlt-1 in response to hypoxia- reperfusion in isolated placental  
332 trophoblast from normal pregnancies (Cindrova-Davies et al, Gabor Lecture Award  
333 Placenta 2009).

334

335 It is also possible that the randomised controlled trials of antioxidants have provided  
336 the antioxidant supplements at too late a stage in gestation. Although the recently  
337 reported study from the USA started antioxidants earlier in pregnancy than the other  
338 trials (9-16 weeks' gestation) (Roberts et al 2010), there has been no study to  
339 address prophylaxis over the periconceptual period. It is of interest that in a large



340 observational study in USA women, Bodnar et al have observed that regular use of  
341 multivitamin preparations in the peri-conceptual period was associated with a 45%  
342 reduction in pre-eclampsia risk compared with non-use (odds ratio 0.32-0.95)  
343 (Bodnar L et al. Am J Epidemiol 2006).

344

### 345 **Alternative Strategies?**

346 Vitamins C and E have little influence on the development of the peroxynitrite radical  
347 (ONOO•) formed from the interaction of nitric oxide (NO•, a nitrogen radical) with  
348 superoxide (O<sub>2</sub>•). In a recent study, Davidge's group showed evidence for up-  
349 regulation of the LOX-1 receptor in the endothelium of small arteries dissected from  
350 omental biopsies obtained during Caesarean section from women with pre-  
351 eclampsia (LOX-1 is the receptor for oxidised LDL), which on gaining access to the  
352 endothelium leads to an inflammatory response, stimulating macrophage  
353 transudation across the endothelial barrier; LOX-1 expression is stimulated by  
354 peroxynitrite and these authors showed *in vitro* that a peroxynitrite scavenger  
355 prevented upregulation of LOX-1 by pre-eclamptic serum in arteries from normal  
356 pregnant women (Sankaralingam S et al, Hypertension 2009). Thus anti-peroxynitrite  
357 strategies may be an alternative evidence-based strategy for reducing oxidative  
358 stress and improving endothelial function in affected women. Here, melatonin may  
359 be a potential candidate as it is a recognised scavenger of ONOO•,

360

361 There is also a recognised association between essential micronutrient selenium  
362 status and pre-eclampsia, which may have implications for a different approach to

363 prevention of oxidative stress. Several selenoproteins, notable the glutathione  
364 peroxidases, play an important role in cellular antioxidant defence by reducing lipid  
365 hydroperoxides to their corresponding un-reactive alcohols and reducing free  
366 hydrogen peroxide to water (Oster & Prellwitz, 1990; Rayman, 2000).  
367 Geographically, there are wide variations in dietary selenium intake depending on  
368 the selenium content of the soil. Pre-eclampsia has been linked to lower placental  
369 tissue, blood and toenail (long term status) selenium status and to reduced activity of  
370 glutathione peroxidases (Mistry et al 2008; Atamer et al, 2005; Rayman et al., 2003).  
371 Our group recently reported increased plasma concentrations of thiobarbituric acid  
372 reactive substances (TBARS; a marker for lipid peroxidation) in maternal and cord  
373 plasma in women with pre-eclampsia compared to controls; moreover, total  
374 glutathione peroxidase activity in both maternal and cord plasma and in placental  
375 tissue was significantly reduced and plasma activity positively related to the plasma  
376 selenium concentration (Mistry, et al. 2008). Selenium supplementation therefore  
377 offers another potential strategy for pre-eclampsia prevention particularly in  
378 geographical regions such as Europe with low soil selenium content (Thomson,  
379 2004). Further prospective, longitudinal studies are required to elucidate a 'cause or  
380 effect' relationship. A small randomised control trial of selenium supplementation  
381 (selenium in pregnancy; SPRINT) conducted in the UK is underway to assess the  
382 impact of selenium supplements on pre-eclampsia related biomarkers. Perhaps  
383 unsurprisingly, dietary selenium insufficiency has been linked to infertility through  
384 oxidative stress.

385


386 Theoretically, statins could play a role in prevention of pre-eclampsia, although  
387 safety in pregnancy must first be established. Statins offer a multi-pronged rationale  
388 as aside from improving the HDL:LDL cholesterol ratio statins have anti-  
389 inflammatory properties, as well as antioxidant effects through inhibition of NADPH  
390 oxidase (Montecucco F, Mach F. Update on statin-mediated anti-inflammatory  
391 activities in atherosclerosis. *Semin Immunopathol.* 2009 Jun;31(1):127-42).

392

393 In summary, oxidative stress is associated with infertility, miscarriage and pre-  
394 eclampsia, but there is at present little convincing evidence that antioxidant  
395 supplements can improve fertility, or prevent miscarriage or pre-eclampsia. The  
396 breadth of strategies attempted has not been extensive, and there is a good  
397 evidence base to indicate well conducted, adequately powered trials which utilise  
398 other approaches. Safety and ethical considerations must however remain a  
399 predominant issue in any move towards other approaches.


400 Figure XX: Plasma g-tocopherol concentration across gestation in 89 women on  
401 placebo and 95 women taking vitamin C and E supplementation; effect of  
402 supplementation: 0.49 (CI 0.43 – 0.57).

403



404

405 Figure XX: Plasma s-flt-1 concentration (logarithmic scale) across gestation in 45  
406 women on placebo and 54 women taking vitamin C and E supplementation;  
407 effect of supplementation: 0.48 (CI 0.19 to 0.67 over 16 weeks),  $p=0.037$ ,  
408 compared to the placebo group.




409

410

411 Figure XX: Plasma PIGF concentration (logarithmic scale) across gestation in 45  
412 women on placebo and 54 women taking vitamin C and E supplementation;  
413 effect of supplementation: 2.1 (CI 1.03 to 4.40 over 16 weeks),  $p=0.037$ ,  
414 compared to the placebo group.

415



416

417

418

419